Furthermore, as the homogenous mutation in FasL has been attributed to autoimmune lymphoproliferative syndrome (ALPS) [18], we also asked if inherited nonlethal mutations in FasL would produce inhibition of Fas signaling, activation, and clustering similar to PPCR mutations in tumors and T cells. The gene discussed is FASLG; the disease is autoimmune lymphoproliferative syndrome.